Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of PA32540 in Patients at Risk for Aspirin-Associated Gastric Ulcers
NCT00995410Phase 3Completed
- Sponsor
- Pozen
- Start
- Oct 2009
- Primary completion
- May 2011
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aspirin + omeprazole in gastric ulcer and cardiovascular diseases (CVD), sponsored by Pozen. Primary endpoint: Number of Subjects Monitored for Long-term Safety of PA32540 at 12 months. Started Oct 2009; status: completed.
02
Drugs
aspirin + omeprazole
03
Conditions
gastric ulcercardiovascular diseases (CVD)
Beyond the preview
Go deeper on NCT00995410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00995410.